Patents by Inventor Jae Won Jeon
Jae Won Jeon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240121948Abstract: A semiconductor device and a method of fabricating the same are provided. According to the present invention, a semiconductor device comprises an active region formed in a substrate, and including flat surfaces and hole-shaped recess portions; upper-level plugs disposed over the flat surfaces; a spacer disposed between the upper-level plugs and providing a trench exposing the hole-shaped recess portions; a lower-level plug filling the hole-shaped recess portions; and a buried conductive line disposed over the lower-level plug and partially filling the trench.Type: ApplicationFiled: December 18, 2023Publication date: April 11, 2024Inventors: Jae Man YOON, Jin Hwan JEON, Tae Kyun KIM, Jung Woo PARK, Su Ock CHUNG, Jae Won HA
-
Publication number: 20220090099Abstract: Provided is a surface expression vector having pgsA, a gene encoding poly-gamma-glutamate synthetase, and a method of expressing a target protein on the microbial surface using the vector. The vector having foreign genes inserted therein is transformed into a microorganism and allows a foreign protein to be stably expressed on the surface of the microorganism.Type: ApplicationFiled: June 24, 2019Publication date: March 24, 2022Inventors: Young Chul PARK, Jae Won JEON, Hong Gyu PARK, Hyun Jun KANG, Se Eun BYEON, Kwang Seo PARK, Dae Eun KI
-
Publication number: 20210238596Abstract: Provided is a pharmaceutical composition for preventing or treating cancer, containing a CD300c expression inhibitor or activity inhibitor; and the like. A CD300c expression inhibitor or activity inhibitor, according to the presently claimed subject matter, in a cancer environment, increases the number of tumor-infiltrating lymphocytes and cytotoxic T cells, reduces the number of myeloid-derived suppressor cells and can effectively inhibit the growth and development of cancer, and thus is expected to be effectively usable as an immunotherapeutic agent in the treatment of various cancers.Type: ApplicationFiled: May 27, 2019Publication date: August 5, 2021Applicant: CENTRICSBIO, INC.Inventors: Jae-Won JEON, Joon-Goo JUNG
-
Patent number: 9856312Abstract: The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.Type: GrantFiled: September 8, 2016Date of Patent: January 2, 2018Assignee: Celltrion Inc.Inventors: Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Hyun Joo Lee, Jae Won Jeon, Hwang Keun Jun, Min Seok Chang
-
Publication number: 20170037113Abstract: The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.Type: ApplicationFiled: September 8, 2016Publication date: February 9, 2017Inventors: Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Hyun Joo Lee, Jae Won Jeon, Hwang Keun Jun, Min Seok Chang
-
Patent number: 9475861Abstract: The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.Type: GrantFiled: September 27, 2012Date of Patent: October 25, 2016Assignee: Celltrion Inc.Inventors: Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Hyun Joo Lee, Jae Won Jeon, Hwang Keun Jun, Min Seok Chang
-
Patent number: 9249220Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: GrantFiled: March 11, 2014Date of Patent: February 2, 2016Assignee: PHARMABCINE INC.Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Patent number: 9249219Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: GrantFiled: March 11, 2014Date of Patent: February 2, 2016Assignee: PHARMABCINE INC.Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Patent number: 9150650Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: GrantFiled: June 26, 2007Date of Patent: October 6, 2015Assignee: PHARMABCINE INC.Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Se-mi Kim, Sang-Seok Koh
-
Patent number: 8993343Abstract: The present invention relates to an anti-inflammatory composition using the antibody specifically binding to CD93 or its soluble fragment, and a diagnostic method and a diagnostic kit for inflammatory disease using CD93 or its soluble fragment specific antibody or aptamer.Type: GrantFiled: January 18, 2010Date of Patent: March 31, 2015Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Young Woo Park, Jae Won Jeon, Joon-Goo Jung, Hye In Choi, Myung-ho Sohn, Ho youn Kim, Mi-La Cho, Young-Soon Jang, Ji-Hun Moon, Ji Hyun Park
-
Publication number: 20140288274Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: ApplicationFiled: March 11, 2014Publication date: September 25, 2014Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Publication number: 20140275488Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicant: PHARMABCINE INC.Inventors: Jin-San YOO, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Publication number: 20140234336Abstract: The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.Type: ApplicationFiled: September 27, 2012Publication date: August 21, 2014Inventors: Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Hyun Joo Lee, Jae Won Jeon, Hwang Keun Jun, Min Seok Chang
-
Publication number: 20130336718Abstract: There is provided a pillar for assembly type furniture comprising: a first pillar that has a first top to be brought in contact with the ceiling and a first bottom positioned at the opposite end to the first top; a second pillar that has a second top wider than the first bottom and a second bottom positioned at the opposite end to the second top, and has a first coupling hole in which the first pillar is inserted as much as a predetermined length, including the first bottom, longitudinally from the second top; a third pillar that is longitudinally combined with the second pillar and has a third top and a third bottom positioned at the opposite end to the third top to be brought in contact with the floor; a coupling mechanism keeping the second pillar and the third pillar longitudinally combined; and an elastic member.Type: ApplicationFiled: July 30, 2013Publication date: December 19, 2013Inventor: Jae won JEON
-
Patent number: 8501175Abstract: The present invention relates to a transmembrane protease, serine (TMPRSS4)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to TMPRSS4. The TMPRSS4-specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.Type: GrantFiled: November 10, 2008Date of Patent: August 6, 2013Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Young Woo Park, So-Young Choi, Young-Soon Jang, Ji Hyun Park, Eun-Jung Song, Jung Yu, Myung-Ho Sohn, Jae Won Jeon, Joon-Goo Jung, Sungsub Kim, Myeoung Hee Jang
-
Publication number: 20120245912Abstract: A method of determining optimal parameters for measuring biological signals of a real body by using a virtual body model modeling a virtual body simulating the real body includes generating a plurality of virtual biological signals of the virtual body using the virtual body model by changing parameters that determine characteristics of the virtual biological signals; selecting at least one of the virtual biological signals based on a characteristic of one of the biological signals of the real body; and outputting at least one parameter used to generate the selected at least one virtual biological signal as at least one optimal parameter for measuring the one biological signal of the real body.Type: ApplicationFiled: February 28, 2012Publication date: September 27, 2012Inventors: Byung-hoon Ko, Sang-kon Bae, Eun-bo Shim, Kun-soo Shin, Min-soo Gyeon, Jae-won Jeon, Seong-bae Hong, Ki-moo Lim, Ah-jin Ryu, Jeong-jae Lee, Jin-ho Song
-
Patent number: 8236312Abstract: The present invention relates to a vascular endothelial growth factor (VEGF)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to VEGF. The VEGF-specific human antibody of the present invention may be used in diagnosis of diseases caused by the VEGF-overexpression, classification of the diseases, visualization, treatment, and prognostic evaluation.Type: GrantFiled: October 16, 2009Date of Patent: August 7, 2012Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Young Woo Park, So-Young Choi, Eun-Jung Song, Jung Yu, Myung-Ho Sohn, Jae Won Jeon, Joon-Goo Jung, Myeoung Hee Jang, Sungsub Kim
-
Publication number: 20120039911Abstract: The present invention relates to an anti-inflammatory composition using the antibody specifically binding to CD93 or its soluble fragment, and a diagnostic method and a diagnostic kit for inflammatory disease using CD93 or its soluble fragment specific antibody or aptamer.Type: ApplicationFiled: January 28, 2009Publication date: February 16, 2012Applicant: Korea Research Institute of Bioscience and BiotechInventors: Young Woo Park, Jae Won Jeon, Joon-Goo Jung, Hye In Choi, Myung-ho Sohn, Ho youn Kim, Mi-La Cho, Young-Soon Jang, Ji-Hun Moon, Ji Hyun Park
-
Publication number: 20110189087Abstract: The present invention relates to a transmembrane protease, serine (TMPRSS4)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to TMPRSS4. The TMPRSS4-specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.Type: ApplicationFiled: November 10, 2008Publication date: August 4, 2011Inventors: Young Woo Park, So-Young Choi, Young-Soon Jang, Ji Hyun Park, Eun-Jung Song, Jung Yu, Myung-Ho Sohn, Jae Won Jeon, Joon-Goo Jung, Sungsub Kim, Myeoung Hee Jang
-
Patent number: D1016322Type: GrantFiled: May 27, 2021Date of Patent: February 27, 2024Assignee: Corentec Co., Ltd.Inventors: Sang-Kil Lee, Seong-Beom Jeon, Jae-Won Kim, Jung-Sung Kim